Cesca Therapeutics loss widens, but cash up as push begins for FDA approval

Cesca Therapeutics Inc. ended its fiscal year June 30 with increased losses but an infusion of cash to launch products into a new market...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.